In conclusion, based on a comprehensive review of the literature, we have developed a gene panel for targeted resequencing of thymic epithelial tumors and confirmed the presence of GTF2I mutations in a subgroup of thymomas among patients with myasthenia gravis. This evidence concerns the gene GTF2I and thymic epithelial neoplasm.